Secreted calmodulin-like skin protein inhibits neuronal death in cell-based Alzheimer's disease models via the heterotrimeric Humanin receptor.
Hashimoto. Y Y; Nawa. M M; Kurita. M M; Tokizawa. M M; Iwamatsu. A A; Matsuoka. M M
Key Findings
- CLSP is secreted and blocks neuronal death in Alzheimer’s‑related cell models
- CLSP activates the heterotrimeric Humanin receptor with an EC50 of 10‑100 pM, far stronger than Humanin itself
- Normal human blood contains ~5 nM CLSP and it can cross into cerebrospinal fluid in mice
Practical Outcomes
- The discovery points to CLSP as a promising target for neuro‑protective supplements or drugs, but it’s still only tested in mice and not yet available as a safe, effective product for humans. Biohackers should watch for future clinical studies before considering any CLSP‑based interventions.
Summary
Scientists found a skin‑derived protein called CLSP that can protect brain cells from death linked to Alzheimer’s disease, working through the same receptor as the peptide Humanin but far more powerfully. It’s naturally present in the blood and can reach the brain’s fluid in mice, hinting it might be a natural brain‑protective factor.
Abstract
Humanin is a secreted bioactive peptide that is protective in a variety of death models, including cell-based neuronal death models related to Alzheimer's disease (AD). To mediate the protective effect in AD-related death models, Humanin signals via a cell-surface receptor that is generally composed of three subunits: ciliary neurotrophic factor receptor α, WSX-1 and gp130 (heterotrimeric Humanin receptor; htHNR). However, the protective effect of Humanin via the htHNR is weak (EC50=1-10 μM); therefore, it is possible that another physiological agonist for this receptor exists in vivo. In the current study, calmodulin-like skin protein (CLSP), a calmodulin relative with an undefined function, was shown to be secreted and inhibit neuronal death via the htHNR with an EC50 of 10-100 pM. CLSP was highly expressed in the skin, and the concentration in circulating normal human blood was ~5 nM. When administered intraperitoneally in mice, recombinant CLSP was transported across the blood-cerebrospinal fluid (CSF)-barrier and its concentration in the CSF reaches 1/100 of its serum concentration at 1 h after injection. These findings suggest that CLSP is a physiological htHNR agonist.
Study Information
pubmed
2013
2013-03-21T00:00:00.000Z
10.1038/cddis.2013.80
26
46